文献速递骨软组织肉瘤与黑色素瘤

免疫荧光联合原位杂交技术检测骨肉瘤循环肿瘤细胞及其临床意义

[Detection and clinical significance of circulating tumor cells in osteosarcoma using immunofluorescence combined with in situ hybridization].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

该研究采用免疫磁珠富集联合免疫荧光与原位杂交(iFISH)检测23例骨肉瘤患者外周血循环肿瘤细胞(CTCs),并分析其与预后的关系。结果显示19例可检出CTCs,复发和(或)转移组CTCs计数为2.846±1.281个,高于无复发和转移组的1.400±1.506个(P=0.021)。作者认为CTCs计数与疾病进展和不良预后相关,可能作为监测转移和复发的潜在预后工具。

要点

  • 免疫磁珠CD45差减富集法富集HOS细胞的回收率>90%。
  • 23例骨肉瘤患者中19例外周血检测到CTCs。
  • 复发和(或)转移组CTCs计数为2.846±1.281个,高于无复发和转移组的1.400±1.506个(P=0.021)。

核心结论

  • 利用iFISH可以检测到骨肉瘤患者外周血CTCs,且CTCs计数与患者的预后有关,CTCs可以作为骨肉瘤患者病情变化的预测指标。

研究设计与样本

  • 采用活体细胞荧光示踪技术验证免疫磁珠富集法回收细胞的能力,应用流式细胞术检测HOS细胞、HepG2细胞和人白细胞中CD45和CK18的表达,采用荧光原位杂交检测HOS细胞染色体倍数异常情况。
  • 采用免疫荧光联合原位杂交技术(iFISH)检测23例骨肉瘤患者外周血CTCs,将患者分为复发或转移组和原发组,分析CTCs计数与患者预后的关系。

主要发现

  • 免疫磁珠CD45差减富集法富集HOS细胞的回收率>90%。
  • 流式细胞术检测显示HOS细胞呈CD45(-)和CK18(-)。
  • CEP8杂交探针信号>2的细胞占总细胞数的96.5%,其中探针信号数为3的细胞占异常细胞的65.0%。
  • 23例骨肉瘤患者中19例外周血中检测到CTCs。
  • 复发和(或)转移患者CTCs计数为(2.846±1.281)个,无复发和转移患者CTCs计数为(1.400±1.506)个,差异有统计学意义(P=0.021)。

关键数值与推荐

  • CTCs鉴定标准为:CEP8阳性信号>2的细胞占总细胞数的96.5%以上,其中阳性信号>3的细胞占65.0%以上。

临床怎么用

  • 原文结论认为CTCs计数与骨肉瘤患者预后有关,可作为骨肉瘤患者病情变化的预测指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical significance of detection of circulating tumor cells (CTCs) in peripheral blood from patients with osteosarcoma (OS) using the iFISH (immunofluorescence and fluorescence in situ hybridization) method. Methods: The live cells recovery rate of immune-magnetic beads was evaluated by live-cell fluorescent tracer technology. The expression of CD45 and CK18 on the cell surface of HOS and HepG2 cells was measured by flow cytometry. And the chromosome aneuploidy was detected by centromeric FISH probe CEP8. Subsequently, 23 OS patients were enrolled and divided into two groups, relapse or metastasis group and primary group. And the prognostic significance of CTCs numbers was analyzed. Results: The live cells recovery rate of immune-magnetic beads was higher than 90%. The flow cytometry results showed that HOS cells were double negative for the surface biomarkers of CD45 and CK18. In addition, the FISH-CEP8 signal abnormality rate were 96.5% in HOS cells. Thus, CTC was identified using the criteria as follows: the cells with CEP8-positive signal >2 accounted for more than 96.5% of the total cells, of which the cells with >3 positive signal were more than 65.0%. Among the enrolled patients, 19 patients had detectable CTCs in the peripheral blood. The CTCs numbers in the relapse or metastasis group and primary group were 2.846±1.281 and 1.400±1.506, respectively. The results showed that the CTCs in patients with recurrence or metastasis were significantly higher than those in primary patients (P=0.021). Conclusions: To our knowledge, this is the first evidence of existence of CTCs in OS patients. The CTCs numbers were positively associated with disease progression and poor prognosis. These results may provide a potential prognostic tool for monitoring metastasis and recurrence in OS patients. Trial registration: Chinese Clinical Trial Registry, ChiCTR-OOC-15005925. 目的: 探讨骨肉瘤患者外周血中循环肿瘤细胞(CTCs)的表达及其与患者预后的关系。 方法: 采用活体细胞荧光示踪技术验证了免疫磁珠富集法回收细胞的能力,应用流式细胞术检测HOS细胞、HepG2细胞和人白细胞中CD45和CK18的表达,采用荧光原位杂交检测HOS细胞染色体倍数异常情况。采用免疫荧光联合原位杂交技术(iFISH)检测23例骨肉瘤患者中外周血CTCs,分析CTCs计数与患者预后的关系。 结果: 免疫磁珠CD45差减富集法富集HOS细胞的回收率>90%。流式细胞术检测显示,HOS细胞呈CD45(-)和CK18(-)。CEP8杂交探针信号>2的细胞占总细胞数的96.5%,其中探针信号数为3的细胞占异常细胞的65.0%。23例骨肉瘤患者中,19例患者外周血中检测到CTCs。复发和(或)转移患者CTCs计数为(2.846±1.281)个,无复发和转移患者的CTCs计数为(1.400±1.506)个,差异有统计学意义(P=0.021)。 结论: 利用iFISH可以检测到骨肉瘤患者外周血CTCs,且CTCs计数与患者的预后有关,CTCs可以作为骨肉瘤患者病情变化的预测指标。 临床试验注册: 中国临床试验注册中心,ChiCTR-OOC-15005925.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang HQ, Li MH, Wang Z, et al. [Detection and clinical significance of circulating tumor cells in osteosarcoma using immunofluorescence combined with in situ hybridization]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28728292. doi:10.3760/cma.j.issn.0253-3766.2017.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。